Template:Pyelonephritis medical therapy: Difference between revisions

Jump to navigation Jump to search
(/* Empiric Therapy for Acute Pyelonephritis (Outpatient & Inpatient) Adapted from Clin Infect Dis. 2011;52(5):e103-20.{{Cite journal | last1 = Gupta | first1 = K. | last2 = Hooton | first2 = TM. | last3 = Naber | first3 = KG. | last4 = Wullt | first4 ...)
No edit summary
 
(7 intermediate revisions by 3 users not shown)
Line 1: Line 1:
==Empiric Therapy for Acute Pyelonephritis (Outpatient & Inpatient) <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from ''Clin Infect Dis. 2011;52(5):e103-20.''<ref name="Gupta-2011">{{Cite journal  | last1 = Gupta | first1 = K. | last2 = Hooton | first2 = TM. | last3 = Naber | first3 = KG. | last4 = Wullt | first4 = B. | last5 = Colgan | first5 = R. | last6 = Miller | first6 = LG. | last7 = Moran | first7 = GJ. | last8 = Nicolle | first8 = LE. | last9 = Raz | first9 = R. | title = International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. | journal = Clin Infect Dis | volume = 52 | issue = 5 | pages = e103-20 | month = Mar | year = 2011 | doi = 10.1093/cid/ciq257 | PMID = 21292654 }}</ref></SMALL></SMALL></SMALL></SMALL></SMALL>==
==Empiric Therapy for Acute Pyelonephritis (Outpatient & Inpatient) <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from ''Clin Infect Dis. 2011;52(5):e103-20.''<ref name="Gupta-2011"<ref>{{Cite journal  | last1 = Gupta | first1 = K. | last2 = Hooton | first2 = TM. | last3 = Naber | first3 = KG. | last4 = Wullt | first4 = B. | last5 = Colgan | first5 = R. | last6 = Miller | first6 = LG. | last7 = Moran | first7 = GJ. | last8 = Nicolle | first8 = LE. | last9 = Raz | first9 = R. | title = International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. | journal = Clin Infect Dis | volume = 52 | issue = 5 | pages = e103-20 | month = Mar | year = 2011 | doi = 10.1093/cid/ciq257 | PMID = 21292654 }}</ref></SMALL></SMALL></SMALL></SMALL></SMALL>==
 


{|
{|
Line 59: Line 58:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen 3'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen 3'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 500 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Ertapenem]] 1 g IV q24h'''''<BR> OR <BR> ▸ '''''[[Doripenem]] 500 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Aztreonam]] 1 g IV q8–12h
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 500 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Ertapenem]] 1 g IV q24h'''''<BR> OR <BR> ▸ '''''[[Doripenem]] 500 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Aztreonam]] 1 g IV q8–12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | <SMALL> '''Antibiotics should be administered for at least 10–14 days based on local resistance patterns.''' <BR> '''De-escalation to oral antibiotcs may be considered 24–48 hours after defervescence.''' </SMALL>
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | <SMALL> '''Antibiotics should be administered for at least 10–14 days based on local resistance patterns.''' <BR> '''De-escalation to oral antibiotcs may be considered 24–48 hours after defervescence.''' </SMALL>
Line 66: Line 65:
|}
|}
|}
|}
==Empiric Therapy for Acute Pyelonephritis (Pregnancy) <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from ''European Association of Urology's Guidelines on Urological Infections'' <ref>{{Cite web  | last =  | first =  | title = http://www.uroweb.org/gls/pdf/18_Urological%20infections_LR.pdf | url =http://www.uroweb.org/gls/pdf/18_Urological%20infections_LR.pdf | publisher =  | date =  | accessdate = }}</ref></SMALL></SMALL></SMALL></SMALL></SMALL>==
{| style="background: #FFFFFF;"
{| style="background: #FFFFFF;"
| valign=top |
| valign=top |
Line 77: Line 79:
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | OR
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | OR
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q6 h
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q6 h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 3-5 mg/kg/day IV in 3 divided doses
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 3-5 mg/kg/day IV in 3 divided doses'''''
|-
|-
|}
|}
|}
|}

Latest revision as of 20:29, 16 May 2014

Empiric Therapy for Acute Pyelonephritis (Outpatient & Inpatient) Adapted from Clin Infect Dis. 2011;52(5):e103-20.[1]

Acute Pyelonephritis, Outpatient
Preferred Regimen
Ciprofloxacin 500 mg PO q12h x 7 days ± Ciprofloxacin 400 mg IV x 1 dose
OR
Ciprofloxacin XR 1000 mg PO q24h for 7 days
OR
Levofloxacin 750 mg PO q24h for 5 days
PLUS (if fluoroquinolone resistance >10%)
Ceftriaxone 1 g IV x 1 dose
OR
Gentamicin 7 mg/kg IV x 1 dose
OR
Tobramycin 7 mg/kg IV x 1 dose
OR
Amikacin 20 mg/kg IV x 1 dose
Alternative Regimen 1
TMP/SMZ 160/800 mg PO q12h x 14 days
PLUS (if TMP/SMZ resistance unknown)
Ceftriaxone 1 g IV x 1 dose
OR
Gentamicin 7 mg/kg IV x 1 dose
OR
Tobramycin 7 mg/kg IV x 1 dose
OR
Amikacin 20 mg/kg IV x 1 dose
Alternative Regimen 2
Amoxicillin–Clavulanate 500/125 mg PO q12h x 14 days
OR
Amoxicillin–Clavulanate 250/125 mg PO q8h x 5–7 days
OR
Cefaclor 500 mg PO q8h x 7 days
PLUS
Ceftriaxone 1 g IV x 1 dose
OR
Gentamicin 7 mg/kg IV x 1 dose
OR
Tobramycin 7 mg/kg IV x 1 dose
OR
Amikacin 20 mg/kg IV x 1 dose
Acute Pyelonephritis, Inpatient
Preferred Regimen
Ciprofloxacin 400 mg IV q12h
OR
Levofloxacin 750 mg IV q24h
Alternative Regimen 1
Gentamicin 7 mg/kg IV q24h ± Ampicillin 500 mg IV q6h
OR
Tobramycin 7 mg/kg IV q24h ± Ampicillin 500 mg IV q6h
OR
Amikacin 20 mg/kg IV q24h ± Ampicillin 500 mg IV q6h
Alternative Regimen 2
Cefotaxime 1–2 gm IV q8h
OR
Ceftriaxone 1 gm IV q24h
OR
Ceftazidime 2 gm IV q8h
OR
Ampicillin-Sulbactam 1.5 g IV q6h
OR
Piperacillin-Tazobactam 3.375 gm IV q4–6h
OR
Ticarcillin-Clavulanate 3.1 gm IV q4–6h
WITH OR WITHOUT
Gentamicin 7 mg/kg IV q24h
OR
Tobramycin 7 mg/kg IV q24h
OR
Amikacin 20 mg/kg IV q24h
Alternative Regimen 3
Meropenem 500 mg IV q8h
OR
Ertapenem 1 g IV q24h
OR
Doripenem 500 mg IV q8h
OR
Aztreonam 1 g IV q8–12h
Antibiotics should be administered for at least 10–14 days based on local resistance patterns.
De-escalation to oral antibiotcs may be considered 24–48 hours after defervescence.

Empiric Therapy for Acute Pyelonephritis (Pregnancy) Adapted from European Association of Urology's Guidelines on Urological Infections [2]

Pyelonephritis, Pregnancy
Preferred Regimen
Ceftriaxone 1-2 g IV or IM q24 h
OR
Aztreonam 1 g IV q8-12 h
OR
Piperacillin-tazobactam 3.375-4.5 g IV q6h
OR
Cefepime 1 g IV q12 h
OR
Imipenem-cilastatin 500 mg IV q6 h
OR
Ampicillin 2 g IV q6 h
PLUS
Gentamicin 3-5 mg/kg/day IV in 3 divided doses
  1. Gupta, K.; Hooton, TM.; Naber, KG.; Wullt, B.; Colgan, R.; Miller, LG.; Moran, GJ.; Nicolle, LE.; Raz, R. (2011). "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases". Clin Infect Dis. 52 (5): e103–20. doi:10.1093/cid/ciq257. PMID 21292654. Unknown parameter |month= ignored (help)
  2. "http://www.uroweb.org/gls/pdf/18_Urological%20infections_LR.pdf" (PDF). External link in |title= (help)